Kiniksa Banner Event Registration
Acralyst Logo
Calendar icon


Globe icon

ARCALYST Steps to Success Webinar: Taking Action and Staying on Track

Time icon

7:00 PM - 8:00 PM ET / 4:00 PM - 5:00 PM PT

Speaker icon

Zenda, Individual living with recurrent pericarditis

Speaker icon

Janice, Kiniksa Patient Access Lead

Location icon


Program Information

Recurrent pericarditis (RP) causes repeated episodes of pain that may affect every part of your life. Learn about taking action and staying on track with RP treatment by joining us for a free webinar.

Zenda, who lives with recurrent pericarditis, will share her experiences with RP and ARCALYST® (rilonacept). Janice, a Kiniksa Patient Access Lead (PAL), will tell you about the support available from the Kiniksa OneConnect™ program.

Dr. David Homan, an interventional cardiologist specializing in recurrent pericarditis, will join Zenda and Janice to explain RP, what causes it, and how reducing risk of flares can be possible with ARCALYST.

ARCALYST Steps to Success Webinar: Taking Action and Staying on Track is intended for the U.S. recurrent pericarditis community and is hosted by Kiniksa Pharmaceuticals. The goal of Kiniksa Pharmaceuticals is to advance therapies for patients suffering from debilitating immunological diseases with significant unmet medical need, including recurrent pericarditis. The biopharmaceutical company is committed to collaborating with and learning from patient organizations and patient advocates to better understand and support the broader needs of the community.

Learn more about ARCALYST by visiting

Please fill out the information below. (*) denotes required field.


  • ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
  • While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.
  • Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
  • Medicines that affect the immune system may increase the risk of getting cancer.
  • Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
  • Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
  • Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.
For more information about ARCALYST, speak with your doctor and see the full Prescribing Information.


ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

  • Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
  • Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
  • Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.
Follow us on social media:
Arcalyst logo
Kiniksa logo

This site is intended for US audiences only.

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. All other trademarks and registered trademarks are the property of their respective owners. Kiniksa OneConnect is a trademark of Kiniksa Pharmaceuticals.

© 2023 Kiniksa Pharmaceuticals (UK), Ltd. All Rights Reserved. 10/23 ARC-US-00294-23